Exagen：転換点を迎えつつある小型の診断薬企業 (NASDAQ:XGN)
· seekingalpha.com
Exagen (XGN) 買い推奨：収益の加速、平均販売価格（ASP）の改善、そして2027年までの収支均衡への道筋。
Exagen (NASDAQ: XGN ) is becoming a very interesting diagnostics company as revenue growth accelerates, average selling prices are improving, and management mov...